Purpose The aim of the current investigation was to develop a population pharmacokinetic model for doxorubicin and doxorubicinol that could provide improved estimated values for the pharmacokinetic parameters clearance of doxorubicin, volume of distribution of the central compartment, clearance of doxorubicinol and volume of distribution of the metabolite compartment for adults and children older than 3 years. A further aim was to investigate the potential influence of the covariates body surface area, body weight, body height, age, body mass index, sex and lean body mass on the pharmacokinetic parameters. Methods Three different datasets, two containing data from adults and one containing data from adults and children, were merged and the combined dataset was analysed retrospectively. In total, the combined dataset contained 934 doxorubicin and 935 doxorubicinol plasma concentrations from 82 patients [64 adults and 18 children (\18 years)]. With this combined dataset, a population pharmacokinetic model was developed, using NONMEM Ò 7.2 and a predefined model-building strategy. Different structural models, error models and estimation methods were tested, and the inter-individual and the inter-occasion variability (variability between separate (two or three) doxorubicin infusions) were tested. Using a subset of 52 patients, the influence of different covariates on the pharmacokinetic parameters was investigated. The pharmacokinetic parameter estimates obtained from doxorubicin concentrations with the best model were fixed, and an additional compartment for doxorubicinol was added to the model. With the final model for both substances, a potential age dependency and body mass index dependency of the 
clearance of doxorubicin and doxorubicinol as well as of the volumes of distribution of the central and the metabolite compartment were evaluated. Results A four-compartment model best described the doxorubicin and doxorubicinol data of the combined dataset. This model included a proportional residual error model and an inter-individual variability on the clearance of doxorubicin, on the inter-compartmental clearances of the peripheral compartments, on the clearance of doxorubicinol and on the volumes of distribution of the central, one peripheral and the metabolite compartment. Furthermore, the body surface area as covariate on all pharmacokinetic parameters and an inter-occasion variability for the clearance of doxorubicin and the volume of distribution of the central compartment were incorporated in the model. For a patient with the body surface area of 1.8 m 2 , the clearance of doxorubicin was 53.3 L/h (inter-individual variability 31 %, inter-occasion variability 13 %) and the volume of distribution of the central compartment was 17.7 L (inter-individual variability 19 %, inter-occasion variability 21 %), respectively. The residual variability of the model was 22 % for doxorubicin and 26 % for doxorubicinol. The clearance of doxorubicinol was estimated at 44 L/h (inter-individual variability 50 %) and the volume of distribution of the metabolite compartment at 1,150 L (inter-individual variability 57 %). The evaluation of a possible age dependency and body mass index dependency showed a trend to a smaller volume of distribution of the central compartment (normalised to the body surface area) and a higher volume of distribution of the metabolite compartment (normalised to the body weight) in younger patients. Conclusions A four-compartment NONMEM Ò model for doxorubicin and doxorubicinol adequately described the plasma concentrations in adults and children ([3 years). No pronounced effects of age on the clearance of doxorubicin or doxorubicinol were found, and the analysis did not support the modification of the dosing strategies presently used in children and adults. 
Introduction
Doxorubicin is an anthracycline antibiotic isolated from streptomyces peucetius. It is an important component in the treatment of various solid tumours and haematological malignancies. Despite its frequent use in adults and children diagnosed with cancer, the mechanisms of action are not completely understood. Doxorubicin is reported to intercalate between base pairs of DNA and to induce free radical formation and lipid peroxidation. Furthermore, direct membrane effects, an inhibition of topoisomerase IIactivity, an induction of apoptosis and an alteration of mitochondrial function are reported [15] . Doxorubicin has a narrow therapeutic index with myelosuppression and cardiotoxicity being the main dose-limiting toxicities [12] .
To dose cytotoxic drugs in children, the linear per kilogram model and the body surface area model are alternative approaches. Doxorubicin dosing is usually based on the patients' body surface area. However, some treatment protocols recommend a body weight-based dosing in newborns and infants, since in this patient group the body surface area is greater compared to the body weight, and thus, a body surface area-based dosing results in higher doses than a body weight-based dosing.
Yet, most doxorubicin dosing regimes are empirical. Since the knowledge about the drug's pharmacokinetics is limited, there is a need for further systematic studies (especially in neonates, infants and very young children). The acquired knowledge could lead to more precise dosing recommendations that would maintain efficacy while reducing toxicity.
Within a dose range of 20-60 mg/m 2 , doxorubicin exhibits linear pharmacokinetics [9] . The plasma concentration-time curve is triphasic. The distribution half-life is 12 min (min) (standard deviation ±8 min). The half-life of the second phase is 3.3 h (±2.2 h), and the elimination half-life is 29.6 h (±13.5 h) [2] . Doxorubicin binds to plasma proteins to about 75 %, the volume of distribution is 20-30 L/kg and the drug is extensively metabolised in the liver, other tissues and the blood. Blum and Carter [3] reported that about 50 % of the parent drug is excreted in bile and that 30 % of doxorubicin is excreted as conjugates. Five to 12 % of the drug is excreted renally [32] . The metabolism of doxorubicin is via carbonyl reduction, reductive-and hydrolytic-glycosidic cleavage, O-demethylation, O-sulfation and O-beta-glucuronidation [30] . Doxorubicinol (dox'ol) is the 13-hydroxyl metabolite of doxorubicin formed by cytoplasmic NADPH-dependent aldoketoreductases. Dox'ol is between 1.5-and 10-fold less potent than doxorubicin in growth inhibition of tumour cell lines [13, 24] . However, it is assumed to contribute to the anthracycline-associated cardiotoxicity [7] .
The pharmacokinetics of doxorubicin and dox'ol show high inter-individual variability and inter-occasion variability [16, 17] . A more than 10-fold inter-patient variation of the area under the concentration-time curve of steadystate concentrations, of clearance values and of dose-normalised doxorubicin plasma concentrations was observed [9, 14, 28] .
In the current investigation, a combined dataset from adults and children was analysed retrospectively. Nonlinear mixed effects modelling with NONMEM Ò was used to develop a population pharmacokinetic model that could estimate the plasma concentrations of doxorubicin and its metabolite dox'ol for adults and children older than 3 years. The final model was used to evaluate the existence of potential age-dependent and body mass index-dependent differences in the clearance or the central volume of distribution of doxorubicin (CL Doxo , V Doxo ) or its metabolite (CL dox'ol , V dox'ol ) between children (3-11 years), adolescents (12-17 years) and adults (C18 years).
Methods
Literature was reviewed for recent population pharmacokinetic studies of doxorubicin published in the last 10 years. From all five studies performing analyses with NONMEM Ò [5, 18, 19, 31, 34] , the full pharmacokinetic datasets were available for the present analysis. One trial was excluded from the outset since it investigated a specific population with high comorbidity and bad performance score [18] . The datasets of Callies et al. [5] , Thompson et al. [31] and Wilde et al. [34] were used for model building, and the dataset of Jörger et al. [19] served for an external model evaluation.
Dataset
The doxorubicin and dox'ol plasma concentration data from the three datasets of Callies et al. [5] , Thompson et al. [31] and Wilde et al. [34] were merged and used to develop a population pharmacokinetic model for doxorubicin and dox'ol using the software NONMEM Ò 7.2 [26] . All three datasets had already undergone a separate population pharmacokinetic analysis with different NONMEM Ò models. All patients gave their written informed consent to the blood sampling. Dataset 1 (Wilde et al. [34] ) contained 258 doxorubicin and 252 dox'ol plasma concentrations of 29 adults (20-59 years) and one adolescent (17 years). All patients were treated for advanced Hodgkin's lymphoma. Analyses of the plasma samples were performed by capillary electrophoresis with laser-induced fluorescence detection (limit of quantification 2 lg/L). In dataset 2 (Callies et al. [5] ), 30 adults (27-73 years) with a metastatic or a locally advanced cancer were included. These patients provided 350 doxorubicin and 357 dox'ol plasma concentrations. Dataset 3 (Thompson et al. [31] ) contained 17 paediatric patients (3-17 years) and five adults (18-22 years) suffering from various cancers. These patients provided 326 doxorubicin and 326 dox'ol plasma concentrations. The samples of the datasets 2 and 3 were analysed with high-performance liquid chromatography and fluorescence detection (limit of quantification 2.5 and 2 lg/L, respectively).
Merging the datasets resulted in a combined dataset that contained 934 doxorubicin and 935 dox'ol plasma concentrations from 82 patients [64 adults; 18 children (\18 years)]. The plasma concentrations ranged from 2 to 2,701 lg/L for doxorubicin and from 2 to 61 lg/L for dox'ol. Details on the patients included in each dataset and details on infusion times and samples are shown in Tables 1 and 2 . Figure 1 shows the doxorubicin and dox'ol concentrations of the four datasets plotted versus time.
Population pharmacokinetic analysis

Model building
The software NONMEM Ò 7. [20] were used. A predefined step-by-step procedure was applied to build the model that best estimated the available doxorubicin plasma concentrations of the combined dataset (Table 3) . First, the best structural model was determined. Since children were included in the analysis, a scaling factor for the pharmacokinetic parameters was considered to be necessary. All pharmacokinetic parameters were scaled to the body surface area (the only scaling factor available for all patients of the combined dataset). The body surface area was modelled as follows: VP i = h p°* (1 ? h j * (BSA imedian BSA )) where VP i was the individual value of the population parameter P, h p was the estimate for the median patient and h j was the parameter estimate describing the fractional change in the pharmacokinetic parameter for an individual with the body surface area BSA i [22] . In a second step, different error models were tested to describe the residual unexplained variability of the model. Furthermore, inter-individual variability (modelled according to an exponential relationship) was tested on each pharmacokinetic parameter and the existence of a covariance in the inter-individual variability was analysed. Various estimation methods were compared, and the inter-occasion variability (variability between two or three doxorubicin infusions; modelled according to an exponential relationship) was tested on the clearance of doxorubicin and on the central volume of distribution. In each step, the decision between models was based on the improvement of the objective function value as a goodness-of-fit parameter on the 1 % significance level (corresponding to a drop of 6.63 points of the objective function value per degree of freedom). Subsequently, the developed model was used to investigate if replacing the body surface area with one of the covariates body weight, allometric body weight, body height, age, body mass index or lean body mass could improve the model. Therefore, the data from Callies et al. [5] were excluded from the combined dataset since the body surface area was the only covariate available for the population of dataset 2. The covariates body weight, body height, age, body mass index and lean body mass were modelled with the equation VP i = h p * (1 ? h j * (COV imedian COVi )). The allometric body weight (WT) was modelled in two ways. Model A was modelled as
0.75 (for the clearance values) and VP i = h p * (WT i /median WT ) (for the volumes of distribution). In model B, a further pharmacokinetic parameter (h add ) was estimated in the equation for the clearance of doxorubicin: VP i = h p * (WT i /median WT )h add . In these equations, VP i was the individual value of the population parameter P, h p was the estimate for the median patient and h j was the parameter estimate describing the change in the pharmacokinetic parameter for an individual with covariate COV i [22] .
After identification of the best covariate, it was tested if the addition of the covariate sex [modelled as VP i = h p * (1 ? h j * sex)] or the covariate analytical centre [modelled as VP i = h p * (1 ? h j * analytical centre)] could improve the model further.
The estimated pharmacokinetic parameters of the final doxorubicin population pharmacokinetic model were fixed and used to include a metabolite compartment for the 13-hydroxyl metabolite dox'ol in the model.
Comparison of age groups and body mass index groups
To investigate the potential impact of the patient age on the major pharmacokinetic parameters CL Doxo , V Doxo , CL dox'ol and V dox'ol , 52 patients (datasets 1 [34] and 3 [31] ; body surface area was the only covariate available for the population of dataset 2 [5] ) were separated into three age groups. The first age group contained 7 children (3-11 years). The second age group included 11 adolescents (12-17 years), and the third age group comprised 34 adults (C18 years). If no age dependency was observed, the patients were separated into three body mass index groups (according to Kromeyer-Hauschild et al. [23] ) to investigate if a body mass index-dependent difference existed in the CL Doxo , the V Doxo , the CL dox'ol or the V dox'ol . The pharmacokinetic parameters (normalised to the body surface area and to the body weight) were checked for significant differences between the three groups. Therefore, the Kruskal-Wallis H test implemented in the software IBM SPSS Statistics 20 was used. If this test showed a significant result, differences between two groups were analysed with the Mann-Whitney U test and Bonferroni correction for multiple comparisons (p \ 0.05 was considered as significant) [1] .
Model evaluation
The internal model evaluation included the inspection of goodness-of-fit plots (plotting observed plasma concentrations over population predictions and individual predictions and conditional weighted residuals over time after dose). Estimated parameters were checked for plausibility and precision (using the standard error), and simulationbased evaluations were performed by a bootstrap analysis and a standardised visual predictive check (each with 1,000 runs) [10, 33] . If the parameter estimates fell into the 95°confidence interval obtained from the bootstrap analysis, the model was considered unbiased. The Pij percentiles of each observation in relation to its 1,000 simulated observations were plotted versus time after dose in the standardised visual predictive check. Pij values should be uniformly distributed between 0 and 1. Dataset 4 was used for an external model evaluation [19] . It contained 232 doxorubicin and 196 dox'ol plasma concentrations of 59 females (30-81 years). All patients were treated for early or advanced breast cancer. Analyses of the plasma samples were performed by high-performance liquid chromatography and fluorescence detection (limit of quantification 1 lg/L). The final model was applied to dataset 4, and parameter estimates were compared to the doxorubicin and dox'ol pharmacokinetic parameters from the analysis of the other datasets [19] .
Results
Population pharmacokinetic analysis
Model building
Using a predefined model-building strategy (Table 3) , a population pharmacokinetic model for doxorubicin and dox'ol was developed. The body surface area was considered to be necessary as scaling factor on all pharmacokinetic parameters as the combined dataset contained data from adults and children. The analyses showed that a structural model with three compartments (estimating the population pharmacokinetic parameters clearance of doxorubicin (CL Doxo ), the inter-compartmental clearances Q 2 and Q 3 , the volume of distribution of the central compartment (V Doxo ) as well as the volumes of distribution of the peripheral compartments V 2 and V 3 ) best described the doxorubicin data of the combined dataset ( Table 1 ). The investigation of the best residual error model revealed that the model including a proportional residual error model was superior to the models with an additional or a combined residual error. A model with an inter-individual variability on the clearance values CL Doxo , Q 2 and Q 3 as well as on the volumes of distribution V Doxo and V 2 with covariances between CL Doxo and V Doxo , CL Doxo and Q 2 , and V Doxo and Q 2 had the lowest objective function value. The first-order conditional estimation method with interaction was used, and the inclusion of an inter-occasion variability on the CL Doxo and the V Doxo gave the best fit to the data. Replacing the body surface area in the model (OFV = 3,096) with body weight (OFV = 3,094), allometric body weight [model A: OFV = 3,095; model B: OFV = 3,094 (h add = 0.77)], body height (OFV = 3,108), age (OFV = 3,121), body mass index (OFV = 3,124) or lean body mass (OFV = 3,093) could not improve the model on the 1 % significance level. When the covariate sex was added to the model with the covariate body surface area, the model did not improve significantly (OFV = 3,096). Thus, sex was excluded from the model. Although the covariate analytical centre improved the objective function value of the model significantly (OFV = 4,797 vs. 4,780), the evaluation of the model (bootstrap analysis, standardised visual predictive check, external evaluation) showed that the model was not robust. Thus, the covariate analytical centre was also excluded from the model. After identification of the final population pharmacokinetic model for doxorubicin, the estimated pharmacokinetic parameters (CL Doxo , V Doxo , Q 2 , Q 3 , V 2 , V 3 , inter-individual variability of CL Doxo , V Doxo , Q 2 , Q 3 , V 2 , covariance between CL Doxo and V Doxo , CL Doxo and Q 2 , V Doxo and Q 2 , interoccasion variability of CL Doxo and V Doxo , h j , unexplained residual variability) were fixed and used to include dox'ol in the model by adding a metabolite compartment with the parameters clearance of dox'ol (CL dox'ol ), volume of distribution of dox'ol (V dox'ol ) and clearance of doxorubicin into the metabolite compartment (Q 4 ) ( Table 4 ; ''Appendix 1''). Comparison of the pharmacokinetic parameters with the values of dataset 2 and 3 which were also analysed with a four-compartment model showed that the estimated pharmacokinetic parameters for doxorubicin lay in between the values of the datasets 2 and 3, while for CL dox'ol and V dox'ol , lower values were estimated.
Coefficients of determination of the graphs plotting the clearance values of doxorubicin and dox'ol, the V Doxo and the V dox'ol (normalised to the body surface area or the body [4] . The graphs plotting the CL Doxo and the V Doxo (normalised to the body surface area) and the V dox'ol (normalised to the body surface area and the body weight) versus the age showed a low correlation with trends to a smaller CL Doxo and V Doxo and a higher V dox'ol in children (Figs. 2, 3) . 
Comparison of age groups and body mass index groups
To evaluate potential age-dependent or body mass indexdependent differences in the clearance or the central volume of distribution of doxorubicin (CL Doxo , V Doxo ) or its metabolite (CL dox'ol , V dox'ol ), the population was divided into three age groups. The CL Doxo , V Doxo , CL dox'ol and V dox'ol of the three age groups (normalised to the body surface area and to the body weight) were analysed for significant differences between the groups. The investigations showed a significant difference in the V Doxo (normalised to the body surface area) and in the V dox'ol (normalised to the body weight) between children younger than 12 years and adults (p \ 0.05) (Fig. 4) . The boxplots showed a smaller V Doxo and a higher V dox'ol in children younger than 12 years and adults and thus support the trend already described above. Neither significant differences between adolescents (12-17 years) and younger children nor between adolescents and adults were observed.
Model evaluation
The goodness-of-fit plots of the final model showed that the doxorubicin and dox'ol plasma concentrations of the combined dataset could be estimated for adults and children. Population predictions and individual predictions were evenly distributed around the line of identity when they were plotted against the observed doxorubicin and dox'ol concentrations (Fig. 5) . For the final model, a bootstrap analysis with 1,000 runs was performed. Of the bootstrap runs, 34 % did not minimise successfully. However, the parameter estimates fell into the 95 % confidence interval and the model was considered unbiased (Table 4 ).
In the standardised visual predictive check with 1,000 runs, the Pij values were uniformly distributed between 0 and 1 over time (Fig. 6) .
Since the external dataset [19] contained only two doxorubicin and dox'ol plasma concentrations that were obtained later than 30 h after the end of infusion, the model had to be adjusted for the external model evaluation. It was necessary to fix the values for the Q 3 and the V 3 . The external model evaluation showed that the estimated pharmacokinetic parameters were similar to the previously estimated values. However, the deviations were greater than 15 % for all pharmacokinetic parameters, except for the clearance of doxorubicin and the covariance between the clearance of doxorubicin and the central volume of distribution as well as for the inter-individual variability of the clearance of dox'ol and of the volume of distribution of the metabolite compartment. The results of the external model evaluation suggest that pharmacokinetic sampling for doxorubicin and dox'ol should be done until at least 48 h to get unbiased results.
Discussion
In this population pharmacokinetic analysis, previously published data of 82 patients [64 adults and 18 children (\18 years)] who received doxorubicin intravenously were merged and analysed retrospectively. The data originated from three datasets that have already undergone a separate pharmacokinetic analysis [5, 31, 34] . Summarising the information of the three population pharmacokinetic analyses, Wilde et al. (dataset 1) used a combined model for doxorubicin and dox'ol with three compartments (two compartments for doxorubicin and one for dox'ol). The body surface area was used as a cofactor on the clearance and the body mass index as a cofactor on the central volume of distribution of doxorubicin [34] . Callies et al. (dataset 2) used a three-compartment population pharmacokinetic model for doxorubicin. In this model, the inter-individual variability and the inter-occasion variability were implemented for the CL Doxo , the Q 2 and the V 2 , the residual variability was modelled using a proportional error model and no scaling parameters were included in the model. For the metabolite, a four-compartment model (three compartments for doxorubicin and one compartment for dox'ol) was used [5] . Thompson et al. [31] (dataset 3) also used a four-compartment model for doxorubicin and dox'ol. In this model, all parameters were linearly scaled to parameters, and log-transformed plasma drug concentrations were used together with the first-order conditional estimation method [19] . Similar to Callies et al. and Thompson et al., it was possible to describe the data of the population of the combined dataset (Table 1 ) with a four-compartment model. This model could describe the pharmacokinetics of doxorubicin and dox'ol in adults and children simultaneously across widely varying sampling times. Evaluations performed for the population support previous studies that suggested only minor differences in the pharmacokinetics of doxorubicin in adults and children [11, 17] . Nevertheless, this statement can only be related to children older than 3 years since the combined dataset did not contain younger children. Since doxorubicin pharmacokinetic data are rare in neonates, infants and very young children, further evaluations of the pharmacokinetic characteristics of the drug in this patient group are ongoing. For example, the EPOC-MS-001-DOXOTrial that is funded by the European Community's Seventh Framework Programme (EudraCT number: 2009-011454-17; ClinicalTrials.gov Identifier: NCT01095926) is currently recruiting patients to collect data that permit more precise dosage recommendations for doxorubicin in this patient group. There are only a few reports on the pharmacokinetics of doxorubicin in children in the literature (Table 5) [6, 8, 14, 17, 27, 28, 31] . To make things even more complicated, these reports had somewhat conflicting results and data are partly controversial. For example, a higher clearance of doxorubicin in patients younger than 10.5 years was reported by Crom et al. [6] when the clearance was normalised to the body weight, but not when it was normalised to the body surface area. In contrast, McLeod et al. [27] reported a trend towards a lower clearance of doxorubicin in children younger than 2 years when the clearance was normalised to the body surface area, but not when it was normalised to the body weight. The observation of a lower clearance of doxorubicin in younger children was supported by Frost et al. who detected a low clearance in an infant aged 3 months and by Eksborg et al. [8, 14] who saw higher peak plasma concentrations in younger children. The current investigation showed a significant difference in the central volume of distribution (normalised to the body surface area) and in the volume of distribution of the metabolite compartment (normalised to body weight) between children younger than 12 years and adults. This suggests that children younger than 12 years might have higher doxorubicin and smaller dox'ol peak plasma concentrations than adults. Furthermore, Frost et al. [14] detected higher doxorubicin peak plasma concentrations in children 2-6 years than in younger and older children, and Hempel et al. [17] and Palle et al. [18] observed no influence of the age on the doxorubicin peak plasma concentrations.
Regarding body composition, a trend to higher doxorubicin peak plasma concentrations in patients with a low body mass index [8] as well as a lower clearance of dox'ol and a lower volume of distribution of the metabolite compartment in patients with body fat [30 % was reported [31] . In accordance with the observation of the current investigation, other trials observed no influence of the body mass index on the clearance of doxorubicin [17, 31] .
Conclusions
For the adults and children (3-73 years) of the present investigation, a modification of the dose regimes currently used (i.e. to a fixed dosing in adults and children) cannot be supported. Therefore, we recommend using the current, usually body surface area-based, dosing for adults and children as long as there is no better scheme available.
According to power calculations, the minimum required sample size to detect a medium effect size of 0.15 for three covariates with a probability level of 0.05 and a power of 80 % was 76 [29] . The sample size of 82 patients in this analysis fulfilled these criteria. However, one has to keep in mind that the power of deciding for the ''best'' covariate is limited due to the retrospective design of the current investigation.
Further limitations of the analysis were that the combined dataset did not contain the tested covariates body weight, body height, age, body mass index, sex and lean body mass for all patients, that the dataset did not contain many various covariates (no information on plasma bilirubin levels, on transaminases or on pharmacogenetics from the patients was available) and that no children younger than 3 years were included in the dataset. Further trials in children (i.e. collecting more information on patients' covariates) are necessary since no data are available for a rationally based dosing regimen of doxorubicin to be recommended for these patients.
